Skip to main content
NAUT
NASDAQ Industrial Applications And Services

Nautilus Posts First Revenue but Delays Broadscale Assay and Resets Voyager Timeline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.72
Mkt Cap
$210.951M
52W Low
$0.62
52W High
$4.31
52W Position info
177% above low
Off High info
60% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NAUT has more than doubled off its 52-week low of $0.62.

Summary

Nautilus Biotechnology achieved first revenue in Q2 2026 but delayed its broadscale assay indefinitely and pushed the Voyager platform launch to 2027, shifting focus to proteoform applications. Cash reserves remain solid at $129.2 million.


Key Events · Earnings and Guidance · NAUT

  • First Revenue Recognized

    A milestone quarter delivered $0.2 million in total revenue, driven by grant funding from the Michael J. Fox Foundation and service revenue from the first Iterative Mapping Early Access Program customer.

  • Broadscale Assay Delayed Indefinitely

    Assay configuration changes failed to sufficiently improve probe candidate performance to support a 2027 launch, and management provided no new timeline for the broadscale consumable kit.

  • Voyager Platform Launch Pushed to 2027

    Pre-orders for the Voyager platform are now expected in early 2027, with instrument shipments beginning in mid 2027, timed to coincide with proteoform assay consumable kits.

  • Cash Runway Remains Solid

    Cash, cash equivalents, and investments totaled $129.2 million as of June 30, 2026, down from $143.4 million at the end of Q1 2026, but still sufficient to fund operations for at least 12 months.


Analysis · NAUT · Industrial Applications And Services

Nautilus Biotechnology recorded its first-ever revenue of $0.2 million in Q2 2026, marking a milestone for the pre-commercial company. However, the quarter was overshadowed by a significant delay in the broadscale assay program, for which no new timeline was provided, and the Voyager platform launch was pushed to early/mid 2027. While the cash position of $129.2 million provides runway, the deferred commercial timelines and a shift in resources toward proteoform applications introduce uncertainty about the path to meaningful revenue. The net loss narrowed slightly and operating expenses declined, but the roadmap reset is the dominant story.

At the time of this filing, NAUT was trading at $1.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $211M. The 52-week trading range was $0.62 to $4.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAUT - Latest Insights

NAUT
Jun 30, 2026, 5:13 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $1.72 info
Change: -$0.150 (-8%) info
Market Cap: $210.951M info
NAUT
Jun 04, 2026, 4:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.68
Real-time Price: $1.72 info
Change: -$0.960 (-36%) info
Market Cap: $210.951M info
NAUT
Apr 28, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.59
Real-time Price: $1.72 info
Change: -$0.870 (-34%) info
Market Cap: $210.951M info
NAUT
Apr 27, 2026, 8:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $1.72 info
Change: -$1.28 (-43%) info
Market Cap: $210.951M info
NAUT
Mar 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.67
Real-time Price: $1.72 info
Change: -$0.9518 (-36%) info
Market Cap: $210.951M info